
|Videos|May 18, 2017
Dr. Kaufman Discusses Durable Responses to Avelumab in Merkel Cell Carcinoma
Author(s)Howard L. Kaufman, MD
Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































